Chinese regulators are implementing stricter scrutiny over offshore incorporation vehicles, making it harder for tech and biotech companies to conduct IPOs. This move is indicative of Beijing's increased caution in overseeing sensitive industries and ensuring comprehensive regulatory oversight.